Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil

Kanzo/Acta Hepatologica Japonica

Volumn 52, Issue 2, 2011, Pages 102-111

  Ozeki, Itaru ^a   Karino, Yoshiyasu ^a   Akaike, Jun ^a   Kimura, Rikuumi ^a   Arakawa, Tomohiro ^a   Nakashima, Tomoaki ^a   Kuwata, Yasuaki ^a   Ohmura, Takumi ^a   Sato, Takahiro ^a   Toyota, Joji ^a  

^a Sapporo Kosei General Hospital   (Japan)

Author keywords

Adefovir dipivoxil; Estimated glomerular filtration rate; Lamivudine resistant hepatitis B mutants; Renal dysfunction; Serum creatinine

Indexed keywords

ADEFOVIR DIPIVOXIL; CREATININE;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; JAPAN; KIDNEY DYSFUNCTION; MALE; SIDE EFFECT;

EID: 79953173992     PISSN: 04514203     EISSN: 18813593     Source Type: Journal    
DOI: 10.2957/kanzo.52.102     Document Type: Article

References (37)

1. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68
2. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263
3. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180
4. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134
5. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90
6. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101
7. Chang TT, Gish RG, de Man RA, et al. A comparison of entecavir and lamivudine for HBeAgpositive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010
8. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514
9. Chang TT, Lai CL, Yoon SK, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430
10. Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 1-7
11. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999; 282: 2305-2312
12. Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebocontrolled trial. AIDS 2001; 15: 1695-1700
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751
14. Marcelline P, Chang TT, Lee Lim SG, et al. Longterm efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-758
15. Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-734
16. Japanese Source.
17. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-993
18. Cihlar T, Lin DC, Pritchard JB, et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates human and rat renal organic anion transporter 1. Molecular pharmacology 1999; 56:570-580
19. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter (hOAT1) and its role in nephrotoxicity of antiviral nucleoside analogs. Nucleos Nucleot Nucleic Acids 2001; 20: 641-648
20. Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32: 734-740
21. Gilead Sciences I. Hepsera (adefovir dipivoxil) package insert, May 2008
22. Vigano M, Lampertico P, Dongiovanni P, et al. A drug transporter gene polymorphism predicts renal tubular toxicity in patients with chronic hepatitis B on long-term adefovir and lamivudine combination. J Hepatol 2010; 52: S7
23. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455
24. Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391-398
25. van Bommel F, de Man R, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80
26. Karras F, Lafaurie M, Furco A, et al. Tenofovirrelated nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070-1073
27. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2003; 40: 1331-1333
28. Izzedine H, Harris M, Perazella MA, et al. The nephrotoxic effects of HAART. Nat Rev Nephol 2009; 5: 563-573
29. Marcelline P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B. N Engl J Med 2003; 348:808-816
30. Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebocontrolled studies. Kidney Int 2004; 66: 1153-1158
31. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770-774
32. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-834
33. Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078-1088
34. Japanese Source.
35. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1353-1355
36. Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year followup. J Hepatol 2008; 48: 923-931
37. Vigano M, Lampertico M, Iavarone GE, et al. High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. J Hepatol 2009; 50: S338-S339